SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Dec 18, 2015

SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: Dec. 18, 2015 · CIK: 0001390478 · Accession: 0001193125-15-407417

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-208330

Date
December 18, 2015
Author
Mark W. Schwartz, Ph.D.
Form
CORRESP
Company
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)

Letter

Re: Galena Biopharma, Inc.; Registration Statement on Form S-3 (Reg. No. 333-208330)

Acceleration Request 333-208330

December 18, 2015

VIA EDGAR

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-6010

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, Galena Biopharma, Inc., a Delaware corporation (“Galena”), respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 5:00 P.M., Washington, D.C. time, on Tuesday, December 22, 2015, or as soon thereafter as is practicable.

In making its request, Galena acknowledges that:

•

should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

•

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve Galena from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

•

Galena may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very truly yours,
Galena Biopharma, Inc.

Show Raw Text
CORRESP
1
filename1.htm

Acceleration Request 333-208330

 December 18, 2015

VIA EDGAR

 Securities and Exchange Commission

 100 F Street, N.E.

 Washington, D.C. 20549-6010

Re: Galena Biopharma, Inc.; Registration Statement on Form S-3 (Reg. No. 333-208330)

Ladies and Gentlemen:

 In accordance with Rule
461 under the Securities Act of 1933, as amended, Galena Biopharma, Inc., a Delaware corporation (“Galena”), respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be
declared effective at 5:00 P.M., Washington, D.C. time, on Tuesday, December 22, 2015, or as soon thereafter as is practicable.

 In
making its request, Galena acknowledges that:

•

should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

•

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve Galena from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and

•

Galena may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very truly yours,

Galena Biopharma, Inc.

By:

/s/ Mark W. Schwartz

Mark W. Schwartz, Ph.D.

President and Chief Executive Officer